CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) announced today its schedule of key
events and presentations at the 2018 AABB Annual Meeting which is taking
place in Boston on October 13 through October 16.
The AABB Annual Meeting is the largest blood banking conference of the
year. Scientists and clinicians from around the world will be attending
to learn about the latest developments in the industry.
Scheduled presentations of interest include the economic impact of
implementing pathogen-reduced platelets at blood centers and hospitals,
additional data reinforcing the clinical utility of pathogen-reduced
platelets, and results from SPARC, Cerus’ European Phase 3 study of
pathogen-reduced red blood cells.
“We are pleased to share with the blood banking community the latest
data on the INTERCEPT Blood System, which further adds to the clinical
body of evidence supporting the use of pathogen-reduction to improve the
safety and availability of the blood supply,” said Dr. Richard Benjamin,
Cerus’ chief medical officer.
“This year, we have 7 oral presentations that we think underscore the
growing interest in pathogen-reduction and increasing awareness on the
risks associated with transfusion transmitted infections,” continued
Benjamin. “Between Cerus and our scientific collaborators, we will have
22 abstract presentations at AABB.”
Company representatives from Cerus will be in the exhibition areas at
booth #2133.
The following is a select list of presentations of interest. All
presentations are listed in Eastern Daylight Time (EDT). A full list of
Cerus related abstracts can be viewed at https://intercept-usa.com/aabb2018.
|
|
|
Saturday, October 13, 2018
|
|
|
|
|
10:00 am – 11:30 am: ST2-15: Neonatal and
Pediatric Platelet Transfusion – Unresolved Clinical Issues;
Convention Center – 253C, Session will include a presentation on
the incidences of transfusion reactions following transfusion of
conventional and pathogen-reduced platelets.
|
|
|
|
Sunday, October 14, 2018
|
|
|
|
1:00 pm – 2:00 pm: MGT4: Platelet
Availability and Economic Impact of Bacterial Risk Reduction
Strategies at US Blood Centers; Convention Center – Hall A
|
|
|
|
1:00 pm – 2:00 pm: BBC104: Complete
Inactivation of Mers-Coronavirus in Human Apheresis Platelets with
Amotosalen and Ultraviolet a Light Treatment; Convention
Center – Hall A
|
|
|
|
4:00 pm – 5:30 pm: SN5-40: Pediatric
Transfusion Medicine: What’s Hot and New? (Mobile ARS);
Convention Center – 157, Session will include a presentation on
the use of pathogen-reduced blood components in pediatric patients.
|
|
|
|
Monday, October 15, 2018
|
|
|
|
7:00 am – 8:15 am: Cerus Industry Workshop, The
Role of Pathogen Reduction in Reversing Blood Component
Commoditization; Convention Center – 252AB
|
|
|
|
8:30 am – 10:00 am: MN1-8: Bacterial
Mitigation Strategies for Platelet Concentrates: The Transfusion
Service Perspective; Convention Center – 157. Session will
include a presentation discussing the impact of implementing
pathogen reduction on utilization, transfusion reactions, and
hospital finances.
|
|
|
|
2:15 pm – 2:30 pm: TS25-MN3-22: Transfusion
of Pathogen Reduced Vs. Conventional Platelets in Pediatric
Patients: An Assessment of Platelet Usage and Incidence of
Transfusion Reactions; Convention Center – 151
|
|
|
|
4:30 pm – 4:45 pm: NIT3-MN4-35:
Amustaline/Glutathione Pathogen-Inactivated RBC in Thalassemia: A
Randomized, Controlled, Phase III Study (SPARC); Convention
Center – 205C
|
|
|
|
4:45 pm – 5:00 pm: BBC4-MN4-33: Simultaneous
Inactivation of Co-Circulating Arboviruses through Nucleic Acid
Crosslinking; Convention Center - 151AB
|
|
|
|
5:00 pm – 5:15 pm: BBC15-MN4-33:
Optimization of Pathogen Reduction Compatibility at 13 Blood
Centers; Convention Center - 151
|
|
|
|
Tuesday, October 16, 2018
|
|
|
|
11:15 am – 11:30am: MGT3-TU3-23: Platelet
Availability and Economic Impact of Bacterial Risk Reduction
Strategies at US Hospitals; Convention Center – 151
|
|
|
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181012005075/en/
Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations
Director
Source: Cerus Corporation